Medical Meetings

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Jun
07
Pomalidomide, bortezomib, and low‐dose dexamethasone vs bortezomib and low-dose dex in lenalidomide-exposed patients with relapsed or refractory MM
In this video, Dr. Paul Richardson (Dana Farber Cancer Institute, Boston) discusses the results of the OPTIMISMM study, an international phase III trial that compares the three-drug combination of(...)
Jun
06
Overview of Multiple Myeloma Clinical Trials Presented at ASCO 2018
In this video, Dr. Paul Richardson (Dana Farber Cancer Institute, Boston) talks about the most exciting multiple myeloma clinical trials presented at ASCO 2018. He comments on the bb2121 Bluebird(...)
Jun
04
An Overview of Multiple Myeloma Research Presented at ASCO 2018
Dr. Luciano Costa highlights some of the most promising multiple myeloma research presented at ASCO 2018.
Jun
04
Value and Cost of Multiple Myeloma Therapy
Dr. Vincent Rajkumar, Mayo Clinic, talks about the value and cost of mulitple myeloma therapy.
Jun
04
Le myélome multiple ASCO 2018 faits saillants
Dr. Philippe Moreau talks about the ongoing clinical trials in multiple myeloma, frontline therapies for young and elderly patients, and the future of CAR-T cell therapy.
Jun
04
Daratumumab in combination with carfilzomib and dexamethasone in lenalidomide-refractory patients with relapsed multiple myeloma
In this video, Dr. Ajai Chari (Icahn School of Medicine, Mt. Sinai Hospital, New York) discusses an update of a phase III study that looks at safety and efficacy of the combination of daratumumab +(...)